# GUIDELINES FOR DIAGNOSING, PREVENTING AND MANAGING CRYPTOCOCCAL DISEASE AMONG ADULTS, ADOLESCENTS AND CHILDREN LIVING WITH HIV

POLICY BRIEF



# GUIDELINES FOR DIAGNOSING, PREVENTING AND MANAGING CRYPTOCOCCAL DISEASE AMONG ADULTS, ADOLESCENTS AND CHILDREN LIVING WITH HIV

POLICY BRIEF



Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV: policy brief

ISBN 978-92-4-005329-8 (electronic version) ISBN 978-92-4-005330-4 (print version)

#### © World Health Organization 2022

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules/).

**Suggested citation** Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV: policy brief. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.

**Sales, rights and licensing.** To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see https://www.who.int/copyright.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Design and layout by 400 Communications Limited.

## 1. BACKGROUND

Cryptococcal disease is one of the most common opportunistic infections among people living with advanced HIV disease and is a major contributor to illness, disability and mortality (1, 2). From 2020 estimates, there are 179,000 cases of cryptococcal antigenemia (infection) globally in 2020, 152,000 cases of cryptococcal meningitis, resulting in 112,000 cryptococcal-related deaths. Despite a reduction in the estimated absolute global burden of HIV-associated cryptococcal meningitis compared to 2014, likely due to ART expansion, cryptococcal disease still accounts for 19% of AIDS-related deaths, similar to 2014 estimates (3). Cryptococcal meningitis is uncommon among children living with HIV.

A public health, people-centred approach leading to the prevention, earlier diagnosis and improved treatment of cryptococcal disease and its complications is critical to reducing the incidence and associated high mortality of cryptococcal meningitis in low- and middle-income countries.

In June 2022, WHO released updated recommendations for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV. These guidelines recommend simpler and safer treatment for cryptococcal disease among people living with HIV (4).

In addition to providing updated recommendations for treating cryptococcal meningitis with combination antifungal therapy regimens, these guidelines include recommendations and good practice guidance on the following:

- the optimal approach to diagnosing cryptococcal meningitis;
- strategies for preventing invasive cryptococcal disease through cryptococcal antigen screening and pre-emptive fluconazole therapy;
- preventing, monitoring and managing amphotericin B drug toxicity;
- recommendations against adjunctive therapy with systemic corticosteroids; and
- recommendations on the timing of antiretroviral therapy (ART) initiation.

Early diagnosis and treatment of cryptococcal meningitis is key to reducing mortality from cryptococcal disease. Health-care professionals should have a low threshold for suspecting cryptococcal meningitis among people with advanced HIV disease.



### **2. RECOMMENDATIONS**

Diagnosis, screening, and prevention of cryptococcar	ineningitis
Lumbar puncture with measurement of cerebrospinal fluid ink test are the preferred diagnostic approaches	(CSF) opening pressure, rapid CSF antigen assay, or CSF India
Screening for cryptococcal antigen followed by pre-emptive people is recommended before ART (re)initiation for adults <100 cells/mm <sup>3</sup>	e antifungal therapy among cryptococcal antigen–positive and adolescents living with HIV who have a CD4 cell count
Screening for cryptococcal antigen can be considered at CE	04 cell count <200 cells/mm <sup>3a</sup>
Induction therapy (2022 recommendations)	
A single high dose (10 mg/kg) of liposomal amphotericin B four doses per day) and fluconazole (1200 mg/daily for adu maximum of 800 mg daily) should be used as the preferred meningitis. Strong recommendation; moderate-certainty evidence for a	with 14 days of flucytosine (100 mg/kg per day divided into lts; 12 mg/kg per day for children and adolescents up to a induction regimen for treating people with cryptococcal dults and low-certainty evidence for children
Alternative induction regimens	
If liposomal amphotericin B is not available: A seven-day course of amphotericin B deoxycholate (1 mg/ four doses per day) followed by seven days of fluconazole adolescents up to a maximum of 800 mg daily). Strong recommendation; moderate-certainty evidence for a	kg per day) and flucytosine (100 mg/kg per day, divided into (1200 mg daily for adults and 12 mg/kg per day for children and dults and low-certainty evidence for children and adolescents
If no amphotericin B formulations are available: 14 days of fluconazole (1200 mg daily, 12 mg/kg per day fo divided into four doses per day). Strong recommendation; moderate-certainty evidence	or children and adolescents) + flucytosine (100 mg/kg per day,
Note: fluconazole + flucytosine is the only recommended o mortality compared with amphotericin B deoxycholate + fl	ral combination regimen and has been associated with lower uconazole (3).
If flucytosine is not available: 14 days of liposomal amphotericin (3–4 mg/kg per day) + † and adolescents up to a maximum of 800 mg daily). Strong recommendation; moderate-certainty evidence for a	luconazole (1200 mg daily, 12 mg/kg per day for children <i>dults</i>
If liposomal amphotericin B and flucytosine are not availab 14 days of amphotericin B deoxycholate (1 mg/kg per day) and adolescents up to a maximum of 800 mg daily). Strong recommendation; moderate-certainty evidence	le: + fluconazole (1200 mg daily, 12 mg/kg per day for children
Note: flucytosine-containing regimens are superior, and ste	ps should be taken to ensure access to this drug.

These guidelines also provide guidance on preventing, monitoring and managing amphotericin B–related toxicity. Table 1 contrasts the monitoring schedules for single high-dose liposomal amphotericin B and amphotericin B deoxycholate.



## **3. ACCESS TO OPTIMAL ANTIFUNGAL** TREATMENT

Access to essential antifungal drugs remains inadequate in many settings, and laboratory monitoring of treatment and drug toxicity continue to be important barriers. Lack of local generic manufacturers and national in-country registration, and the higher cost of therapeutics, are some of the main barriers. Challenges exist to acquiring each drug that is part of the preferred regimen.

Liposomal amphotericin B is included in the 2021 WHO List of Essential Medicines and WHO Prequalification Expression of Interest list (5, 6). Although liposomal amphotericin B has been off patent since 2016 and there are preferential pricing arrangements from the originator for some countries, the current price of liposomal amphotericin B remains substantially higher than that of amphotericin B deoxycholate in most countries. As of February 2022, liposomal amphotericin B was only registered in two countries in sub-Saharan Africa (Ethiopia and South Africa).

Fluconazole is widely registered and is available in low- and middle-income countries. However, several countries have not included fluconazole in their national list of essential medicines.

Flucytosine is not widely registered or available in most low- and middle-income countries and registering standard formulations of flucytosine is the current priority. A sustained-release formulation is currently being developed to simplify inpatient and outpatient treatment of cryptococcal infections.

Antifungal medications for treating cryptococcal meningitis can be made more accessible through a range of strategies (see Box 1).

#### Box 1. Strategies to increase access to essential medicines for cryptococcal meningitis

Barriers to accessing antifungal medications for treating cryptococcal meningitis can be overcome by:

- increasing advocacy for reducing drug prices and promoting generic production, especially for liposomal amphotericin B and oral flucytosine;
- prioritizing quality assurance of newly available generic formulations;
- ensuring national registration of all cryptococcal meningitis drugs and including them in national essential medicine lists (amphotericin B deoxycholate, liposomal amphotericin B, flucytosine and fluconazole are all included in the WHO Model List of Essential Medicines);

#### 预览已结束, 完整报告链接和二维码如下:



https://www.yunbaogao.cn/report/index/report?reportId=5\_31508